I. AMENDMENTS TO THE CLAIMS:

Claim 1. (Currently Amended) A drug delivery composition comprising 2-[2-(nitrooxy)ethoxy]ethyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate in melted form absorbed/adsorbed onto/into particles, wherein the particles comprise materials selected from the group consisting of mannitol and lactose, optionally in admixture with one or more substances selected from the group consisting of microcrystalline cellulose, cellulose and starch.

Claim 2. (Canceled)

Claim 3. (Currently Amended) The drug delivery composition according to ~~any one of claims~~ claim 1, [[to 2]] wherein the particles have a size between 50 and 500 μm.

Claim 4. (Original) The drug delivery composition according to claim 3 wherein the particles have a size between 100 and 150 μm.

Claim 5. (Currently Amended) The drug delivery composition according to ~~any one of claims~~ claim 1, [[to 4]] wherein the particles have a pore size between 10 and 1000 Å.

Claim 6. (Original) The drug delivery composition according to claim 5 wherein the particles have a pore size between 20 and 750 Å.

Claim 7. (Currently Amended) The drug delivery composition according to ~~any one of claims~~ claim 1, [[to 6]] comprising particles comprising 2-[2-(nitrooxy)ethoxy]ethyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate in admixture with one or more surfactant(s).

Claim 8. (Currently Amended) The drug delivery composition according to ~~any one of claims~~ claim 1, [[to 6]] comprising a combination of
a) particles comprising 2-[2-(nitrooxy)ethoxy]ethyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate and one or more surfactant(s),
and

b) particles comprising 2-[2-(nitrooxy)ethoxy]ethyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate without surfactant.

Claim 9. (Currently Amended) The drug delivery composition according to claims 7 [[and]] or 8, wherein the surfactant(s) is a non-ionic surfactant.

Claim 10. (Original) The drug delivery composition according to claim 9 wherein the surfactant(s) is a block co-polymer.

Claim 11. (Original) The drug delivery composition according to claim 9 wherein the surfactant(s) is a poloxamer.

Claim 12. (Currently Amended) The drug delivery composition according to claims 7 [[and]] or 8, wherein the ratio drug:surfactant(s) is from 1:0.1 to 1:10 (w/w).

Claim 13. (Currently Amended) The drug delivery composition according to ~~any one of claims~~ claim 1, [[to 12]] wherein the particles comprising the drug, optionally in admixture with one or more surfactant(s), are mixed with pharmaceutically acceptable diluent, excipients and/or inert carrier.

Claim 14. (Currently Amended) The drug delivery composition according to ~~any one of claims~~ claim 1, [[to 13]] wherein the particles comprising the drug are formulated into a tablet.

Claim 15. (Currently Amended) The drug delivery composition according to ~~any one of claims~~ claim 1, [[to 13]] wherein the particles comprising the drug are filled into a capsule.

Claim 16. (Currently Amended) The drug delivery composition according to ~~any one of claims~~ claim 1, [[to 13]] wherein the particles comprising the drug are suspended in a water solution.

Claim 17. (Currently Amended) The drug delivery composition according to claims 14 [[and]] or 15, ~~which~~ wherein said composition is coated.

Claim 18. (Currently Amended) The drug delivery composition according to ~~any one of the claims~~ claim 1, [[to 17,]] for use in the treatment of pain and/or inflammation.

Claim 19. (Currently Amended) ~~Use of the drug delivery composition according to any one of the claims 1 to 17~~ A method for the manufacture of a medicament for the treatment of pain and/or inflammation, comprising using the drug delivery composition according to claim 1.

Claim 20. (Currently Amended) A method of treatment of pain and/or inflammation, comprising administration to a patient in need of such treatment, the drug delivery composition according to ~~any one of the claims~~ claim 1[[to 17]].

Claim 21. (Original) A process for preparing particles comprising 2-[2-(nitrooxy)ethoxy]ethyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate comprising mixing the drug in melted form with particles.

Claim 22. (Original) A process for preparing particles comprising 2-[2-(nitrooxy)ethoxy]ethyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate comprising:

a) melting the drug,
b) adding the particles,
c) stirring the obtained mixture,
d) recovering the porous particles comprising the drug.

Claim 23. (Original) A process for preparing particles comprising 2-[2-(nitrooxy)ethoxy]ethyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate comprising:

a) mixing the drug with the particle,
b) melting the obtained mixture,
c) stirring the obtained mixture,

d) recovering the particles comprising the drug.

Claim 24. (Original) A process for preparing particles comprising 2-[2-(nitrooxy)ethoxy]ethyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate and one or more surfactant(s) comprising:

a) melting the drug and the surfactant(s),

b) adding the particles,

c) stirring the obtained mixture,

d) recovering the particles comprising the drug and the surfactant(s),

with a) and b) in optional order.

Claim 25. (Original) The processes according to any one of claims 22 to 24 whereby the drug in step a) is pre-heated.

Claim 26. (Original) A process for the preparation of the drug delivery composition according to claims 14 or 15 comprising;

a) mixing the particles, obtained according to any one of the processes of claims 21 to 25, with pharmaceutically acceptable diluent, excipients and/or inert carrier,

b) granulating the obtained mixture with water,

c) drying the granulate,

d) optionally mixing the granulate with further diluent, excipients and/or inert carrier, and

e1) filling the granulate into capsules,

or

e2) compressing the granulate into tablets.